Awareness campaign for Children’s Neuroblastoma Cancer Foundation wins GCG Marketing honors

GCG Marketing today announces its award of Best Corporate Advertisement/Campaign at the 2009 Medical Marketing & Media Awards honoring the agency’s development of an awareness campaign for the Children’s Neuroblastoma Cancer Foundation.

The campaign featured gripping headlines alongside haunting photographs of children living with neuroblastoma, taken by Fort Worth’s Geno Loro Jr. The award is the second national healthcare honor GCG has received for the campaign this year, following a Manny award for Best Philanthropic Campaign by Med Ad News, and the campaign also garnered local and district ADDY® awards from the American Advertising Federation. Earlier this year, GCG was named one of the top 75 healthcare marketing agencies by Medical Marketing & Media magazine.

“The continued recognition we’ve received for our work on the CNCF campaign is a true honor,” said Neil Foster, GCG Marketing president. “Neuroblastoma is an awful disease in need of greater awareness, and we’re hopeful that both the campaign and these awards help facilitate the discussion of funding for research options.”

Source:

GCG Marketing

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients